StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) income statement

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$147.82−1.58 (-1.06%)

Close on Nov 19, 2026Market cap $19.80BP/E 7.7Yield –

Alnylam Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
77.4%
Operating margin
19.5%
Net margin
52.8%
Return on equity, FY2025
73.3%

Financial strength

Current ratio
2.48
Debt to equity
–
Debt to assets
–
Cash to current liabilities
85.0%

Valuation

P/E ratio
7.7
Price to sales
3.95
Price to book
5.49
Dividend yield
–

See a number that looks wrong?